ALT Share Price Performance
US$5.03
-3.37 (-40.12%)
71.9% undervalued intrinsic discount
US$17.88
Fair Value
Price US$5.03
AnalystConsensusTarget US$17.88
Fair ValueUS$17.88
Share Pricen/a
Altimmune, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 41 Fair Values set on narratives written by author
ALT Community Narratives
AN
Fair Value US$17.88 71.9% undervalued intrinsic discount
Dual Agonist Liver Disease Advances Will Drive A Future Multi Indication Metabolic Franchise
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Dual Agonist Liver Disease Advances Will Drive A Future Multi Indication Metabolic Franchise
Catalysts About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing pemvidutide, a novel dual glucagon and GLP-1 agonist, for serious liver and metabolic diseases including MASH, AUD and ALD. What are the underlying business or industry changes driving this perspective?Read more
74
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$17.88
71.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
2.16k% p.a.
Profit Margin
0.43%
Future PE
28.17x
Price in 2028
US$0.12
Trending Discussion
Recently Updated Narratives
AN
Dual Agonist Liver Disease Advances Will Drive A Future Multi Indication Metabolic Franchise
Fair Value: US$17.88 71.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Altimmune, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.80
- -338,920.00%
- -419,575.00%
- 7.8%
About ALT
- Founded
- 1997
- Employees
- 59
- CEO
- WebsiteView website
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
